Skip to content

US · AMLX · BIOTECHNOLOGY

Amylyx Pharmaceuticals, Inc. (AMLX) intrinsic value and stock valuation

$26.02as of 2026-11-21 · Mkt cap 2.43B

Data updated · price as of 2026-11-21

IC valuationIntrinsic value, upside vs price and the fair-value band are available to Pro members.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Amylyx Pharmaceuticals, Inc. DCF and intrinsic value

InvestorsCraft values AMLX with the Chepakovich two-stage DCF model. How the model works · Run your own DCF prefilled from AMLX’s statements →

Amylyx Pharmaceuticals, Inc. Graham Number

The Graham Number is not defined for negative earnings or book value. Guide · Calculator →

Healthcare · Biotechnology Cambridge, MA 02142 amylyx.com

How the business is doing

Fiscal 2019–2025, USD

Revenue
$0.00
20192025
Net income
-$-144.74M
20192025
Free cash flow
-$-123.48M
20192025
Total equity
$305.3M
20192025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2019–2025, USD
20252024202320222021
Revenue$0.00$87.4M$380.8M$22.2M$0.00
Operating income-$-153.29M-$-314.73M$38.8M-$-201.34M-$-82.69M
Net income-$-144.74M-$-301.74M$49.3M-$-198.38M-$-87.93M
EPSd-$-1.53M-$-4.43M$704K-$-2.98M-$-1.52M
Operating cash flow-$-123.34M-$-167.65M$11.9M-$-179.87M-$-74.8M
Capital expenditure-$-140K-$-160K-$-1.24M-$-2.53M-$-350K
Free cash flow-$-123.48M-$-167.8M$10.7M-$-182.4M-$-75.15M
Total assets$332.6M$193.6M$517.5M$391.5M$105.6M
Total debt$5.96M$1.98M$4.24M$6.28M$0.00
Net debt-$-220.69M-$-75.41M-$-165.96M-$-56.25M-$-50.19M
Total equity$305.3M$164.8M$433.4M$340.6M-$-151.17M
Cash and short-term investments$317M$176.5M$371.4M$346.9M$96.1M
Income statement
20252024202320222021
Revenue$0.00$87.4M$380.8M$22.2M$0.00
Cost of revenue$530K$42.2M$25.4M$2.99M$0.00
Gross profit-$-530K$45.2M$355.4M$19.2M$0.00
Research and development expenses$90.4M$104.1M$128.2M$93.5M$44M
Selling, general and administrative expenses$62.9M$114.3M$188.4M$127.1M$38.9M
Other expenses$0.00$141.5M$0.00$0.00-$-280K
Operating expenses$152.8M$360M$316.5M$220.6M$82.7M
Cost and expenses$153.3M$402.1M$342M$223.6M$82.7M
Interest income$9.3M$13.8M$16.2M$4.29M$40K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$530K$900K$1.09M$490K$50K
Ebitda-$-144.16M-$-290.98M$55.4M-$-197.11M-$-87.88M
Operating income-$-153.29M-$-314.73M$38.8M-$-201.34M-$-82.69M
Total other income/expenses, net$8.6M$12.6M$15.5M$3.74M-$-5.24M
Income before tax-$-144.69M-$-302.14M$54.3M-$-197.6M-$-87.93M
Income tax expense$50K-$-390K$5.03M$770K$0.00
Net income-$-144.74M-$-301.74M$49.3M-$-198.38M-$-87.93M
Weighted average shares outstanding$94.6M$68.1M$67.2M$66.5M$57.9M
Weighted average diluted shares outstanding$94.6M$68.1M$70M$66.5M$57.9M
Balance sheet
20252024202320222021
Cash and short-term investments$317M$176.5M$371.4M$346.9M$96.1M
Net receivables$90K$450K$40.1M$15.3M$0.00
Inventory$0.00$0.00$38.3M$9.77M$0.00
Total current assets$323.7M$189.4M$464.7M$382.1M$105M
Property, plant and equipment, net$5.49M$2.73M$6.41M$8.13M$470K
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$0.00$0.00$0.00$0.00$0.00
Total non-current assets$8.97M$4.2M$52.8M$9.32M$660K
Total assets$332.6M$193.6M$517.5M$391.5M$105.6M
Accounts payable$3.52M$2.94M$22.1M$6.26M$4.37M
Short-term debt$1.26M$1.52M$2.26M$2.04M$0.00
Deferred revenue$0.00$0.00$0.00$0.00$0.00
Total current liabilities$22.7M$28.4M$82M$46.6M$17.4M
Long-term debt$4.7M$460K$1.98M$4.24M$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$4.7M$460K$1.98M$4.24M$239.4M
Capital lease obligations$1.26M$1.98M$4.24M$6.28M$0.00
Total liabilities$27.4M$28.9M$84M$50.9M$256.8M
Common stock$10K$10K$10K$10K$0.00
Retained earnings-$-751.43M-$-606.69M-$-304.95M-$-354.22M-$-155.84M
Accumulated other comprehensive income (loss)$400K-$-90K$200K-$-90K$10K
Total equity$305.3M$164.8M$433.4M$340.6M-$-151.17M
Total investments$90.3M$99.1M$201.2M$284.4M$45.9M
Total debt$5.96M$1.98M$4.24M$6.28M$0.00
Net debt-$-220.69M-$-75.41M-$-165.96M-$-56.25M-$-50.19M
Cash flow statement
20252024202320222021
Net income-$-144.74M-$-301.74M$49.3M-$-198.38M-$-87.93M
Depreciation and amortization$530K$900K$1.09M$490K$50K
Stock-based compensation$27.6M$33M$37.2M$21.7M$3.14M
Change in working capital-$-1.08M-$-45.83M-$-65.66M-$-1.64M$4.59M
Accounts receivable$380K$39.6M-$-24.74M-$-15.31M-$-140K
Inventory$0.00-$-9.25M-$-73.13M-$-9.77M$0.00
Accounts payable$580K-$-19.1M$15.9M$1.85M$670K
Net cash provided by operating activities-$-123.34M-$-167.65M$11.9M-$-179.87M-$-74.8M
Investments in property, plant and equipment-$-140K-$-160K-$-1.24M-$-2.53M-$-350K
Acquisitions, net$0.00$0.00$0.00$236.5M$0.00
Net cash used for investing activities$14M$75.7M$92.1M-$-238.99M-$-46.41M
Common stock issued$260.4M$2.13M$6.86M$432.5M$0.00
Common stock repurchased$0.00$0.00$0.00$0.00$0.00
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities$257M$350K$3.54M$431.8M$158.5M
Net change in cash$148.8M-$-92.08M$107.7M$12.9M$37.3M
Cash at end of period$227.6M$78.8M$170.2M$63.2M$50.4M
Operating cash flow-$-123.34M-$-167.65M$11.9M-$-179.87M-$-74.8M
Capital expenditure-$-140K-$-160K-$-1.24M-$-2.53M-$-350K
Free cash flow-$-123.48M-$-167.8M$10.7M-$-182.4M-$-75.15M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Amylyx Pharmaceuticals, Inc.

        Amylyx Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm, primarily focused on creating therapies for amyotrophic lateral sclerosis (ALS) and various other neurodegenerative conditions. A key asset in its developmental pipeline is AMX0035, a proprietary dual UPR-Bax apoptosis inhibitor. This compound, which integrates sodium phenylbutyrate and taurursodiol, is under investigation for treating ALS, and its application is also being explored for other neurodegenerative diseases. The company was established in 2013 and is based in Cambridge, Massachusetts.

        CEO
        Joshua Cohen
        Employees
        136
        Beta
        -0.20

        Explore

        Frequently asked questions

        What is the intrinsic value of Amylyx Pharmaceuticals, Inc. (AMLX)?

        InvestorsCraft does not currently publish an intrinsic value for AMLX. How the IC value is calculated.

        Is AMLX undervalued?

        InvestorsCraft does not publish an undervaluation signal for AMLX at this time.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.